We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.01%
This Fund
S&P 500
This Quarter Est. Return
+7.49%
1 Year Est. Return
+62.01%
3 Year Est. Return
+164.15%
5 Year Est. Return
+274.12%
10 Year Est. Return
+2,470.02%
AUM
$1.25B
AUM Growth
+$136M
Cap. Flow
+$60.6M
Cap. Flow %
4.87%
Top 10 Hldgs %
22.84%
Holding
2,021
New
430
Increased
368
Reduced
444
Closed
703

Sector Composition

Rank Sector Weight
1 Technology 16.16%
2 Communication Services 12.62%
3 Healthcare 9.79%
4 Consumer Discretionary 7.25%
5 Industrials 4.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTRA icon
251
Natera
NTRA
$38.7B
$945K 0.08%
105,150
-15,853
-13% -$171K
HRTX icon
252
Heron Therapeutics
HRTX
$96.8M
$944K 0.08%
52,163
+14,120
+37% +$230K
MDR
253
DELISTED
McDermott International
MDR
$937K 0.08%
47,457
+21,957
+86% +$464K
CORT icon
254
Corcept Therapeutics
CORT
$12.2B
$936K 0.08%
51,801
+19,452
+60% +$352K
GILD icon
255
Gilead Sciences
GILD
$163B
$932K 0.07%
13,014
+3,648
+39% +$277K
KMT icon
256
Kennametal
KMT
$2.66B
$932K 0.07%
19,255
-22,144
-53% -$987K
FRC
257
DELISTED
First Republic Bank
FRC
$923K 0.07%
10,652
+1,617
+18% +$153K
NBL
258
DELISTED
Noble Energy, Inc.
NBL
$923K 0.07%
+31,669
New +$867K
TWTR
259
DELISTED
Twitter, Inc.
TWTR
$921K 0.07%
38,365
-21,985
-36% -$452K
LRCX icon
260
Lam Research
LRCX
$369B
$920K 0.07%
50,000
-288,430
-85% -$5.67M
ALXN
261
DELISTED
Alexion Pharmaceuticals
ALXN
$919K 0.07%
+7,683
New +$936K
BMRN icon
262
BioMarin Pharmaceuticals
BMRN
$11.6B
$913K 0.07%
10,236
+7,742
+310% +$673K
CP icon
263
Canadian Pacific Kansas City
CP
$79.7B
$911K 0.07%
+24,915
New +$868K
FMB icon
264
First Trust Managed Municipal ETF
FMB
$2.05B
$910K 0.07%
+17,012
New +$908K
HLT icon
265
Hilton Worldwide
HLT
$70.7B
$904K 0.07%
11,317
+1,242
+12% +$92.1K
AON icon
266
Aon
AON
$75.9B
$899K 0.07%
+6,711
New +$955K
EW icon
267
Edwards Lifesciences
EW
$51.1B
$895K 0.07%
+23,826
New +$874K
PR
268
Permian Resources
PR
$17.5B
$889K 0.07%
44,900
+34,700
+340% +$674K
RTN
269
DELISTED
Raytheon Company
RTN
$889K 0.07%
4,731
+1,701
+56% +$317K
TDOC icon
270
CALL
Teladoc Health
TDOC
$1.21B
$878K 0.07%
+25,200
New +$837K
AJG icon
271
Arthur J. Gallagher & Co
AJG
$63.7B
$873K 0.07%
13,794
-4,859
-26% -$310K
CHD icon
272
Church & Dwight Co
CHD
$23.7B
$868K 0.07%
17,302
+6,907
+66% +$324K
BSX icon
273
Boston Scientific
BSX
$72B
$858K 0.07%
34,601
-11,939
-26% -$329K
PEG icon
274
Public Service Enterprise Group
PEG
$38.2B
$857K 0.07%
16,639
+246
+2% +$12.4K
AAN.A
275
DELISTED
The Aaron's Company Inc Class A
AAN.A
$853K 0.07%
21,400
+20,600
+2,575% +$821K

Similar funds

Prelude Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Prelude Capital Management held 2,021 positions worth $1.25B, up 12% from $1.11B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Prelude Capital Management deployed $60.6M of net new capital in Q4 2017, opening 430 new positions and adding to 368 existing holdings. Its largest new stake was Twenty-First Century Fox, Inc. Class B: 328,795 shares worth $11.2M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 16% a quarter earlier, followed by Communication Services and Healthcare.

On the sell side, the largest reduction was Western Digital, an estimated $7.02M trimmed.

  • Prelude Capital Management's largest Q4 2017 buy was Twenty-First Century Fox, Inc. Class B: 328,795 shares worth $11.2M.
  • Prelude Capital Management added most to NXP Semiconductors in Q4 2017, an estimated $28M increase.
  • Prelude Capital Management's biggest Q4 2017 reduction was Western Digital, cutting an estimated $7.02M.
  • Prelude Capital Management fully exited CR Bard Inc. in Q4 2017, selling an estimated $30M.
  • Prelude Capital Management's ten largest holdings make up 23% of its $1.25B portfolio in Q4 2017.
  • Prelude Capital Management opened 430 new positions and closed 703 in Q4 2017.
  • Prelude Capital Management's portfolio value rose 12% quarter-over-quarter to $1.25B.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.